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ABSTRACT
THE Q RULE IN BACTERIODETES AND THE IDENTIFICATION AND
CHARACTERIZATION OF PORPHYROMONAS GINGIVALIS GLUTAMINYL
CYCLASE
John Andrew Houston
November 30th, 2018
Background: Porphyromonas gingivalis, a major pathogen associated with chronic
periodontitis, secretes variety of proteins, majority of which begins with glutamine.
Several of these proteins were found with pyroglutamate (pGlu) at N-terminus
suggesting the presence of this posttranslational modification pathway in
P.gingivalis. The observation that N-terminal glutamine is over-represented as the
first amino acid after signal peptide cleavage, and subsequent confirmation of pGlu
formation on the nascent protein via mass spectrometry, led us to conclude that
an enzyme must be present as the executor of this reaction. Hypothesis: PG2157
is a glutaminyl cyclase and is responsible for the cyclization of N-terminal
glutamine residues. Methods: A homology search was used to identify a gene
(PG2157) encoding a protein homologous to human glutaminyl cyclase (QC) in the
P. gingivalis genome. The gene was cloned, expressed in E. coli and recombinant
PgQC purified. The protein was crystalized, and structure determined by molecular
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replacement. The rPgQC activity was characterized with respect to pH, ionic
strength, optimum substrate specificity, and sensitivity to inhibition by an array of
non-specific and specific inhibitors. Finally, subcellular localization of PgQC in P.
gingivalis was determined. Results: PgQC specificity is restricted for N-terminal
glutamine. The enzyme converts this residue to pGlu with kcat/Km at 1.34 s-1. The
reaction was fastest at low ionic strength and at pH around 8.0. The activity was
inhibited by o-phenanthroline (≥100µM) and EDTA (≥100mM EDTA). Cu2+ and
Zn2+ at ≥100nM exerted ≥90% inhibition.

The activity was also significantly

affected by cysteamine, imidazole, and reduced glutathione. In bacterial cells
PgQC was found associated with the inner membrane as a lipoprotein facing the
periplasm. The crystalline structure of PgQC showed strong similarity to human
QC on the atomic level. Nevertheless, an inhibitor specific for human QC had a
limited effect on the PgQC activity. Conclusions: PgQC is an enzyme resembling
mammalian QC and it is responsible for pyroglutamination of proteins secreted by
the T9SS of P. gingivalis. This activity is likely essential for bacterium viability
since all attempts to produce a viable PgQC knockout failed. Taking into account
that also T. forsythia and P. intermedia possess similar enzymes and the frequency
of the Q value of Bacteriodetes it is likely that similar post-translatonal modification
plays a pivotal role in protein secretion by these periodontal pathogens. Therefore,
inhibition of bacterial QC may represent a novel approach to treat periodontal
diseases.
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CHAPTER I: INTRODUCTION
Periodontal Disease
A periodontal diagnosis is a term that serves as a crucial determination of a
patient’s dental treatment outcome. Clinicians assign these diagnoses on patients
as a culmination of the sum of all the clinical information, pertinent medical history,
and dental history along with the gross findings from a completed periodontal and
oral examination. All the clinical data along with the totality of signs and symptoms
are aggregated together and with this sum of information the clinician may arrive
at a diagnosis. Additionally, sometimes in more complicated cases, additional lab
tests or supplemental information can be instrumental in coming to the correct
conclusion. As a clinician, treatment of plaque-induced periodontal diseases
generally results in the resolution of the periodontal infection. Also, it is vital to
understand that periodontal treatment generally changes the pretreatment
diagnosis to a usually more favorable post-treatment diagnosis. To demonstrate,
effective prophylactic treatment routinely converts mild, moderate, and severe
plaque-induced gingivitis into a state of periodontal health, when stressed with
adequate home care instructions. To further illustrate this point, successful
treatment of plaque-induced periodontitis, when followed up at re-evaluation
appointment, will often be converted to a state of periodontal health with reduced
periodontium, indicating that treatment has achieved the goal of creating shallower
pocket depth measurements.
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Periodontal disease is term that encompasses multiple differential modalities into
one general disease term. Within the diagnosis of periodontal disease, there are
more diverse classification systems that both clinicians and researchers alike use.
The most descriptive and thorough clinical classification system was described by
Armitage in 1999, and is still utilized by clinicians today [1].
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Table 1 Presentation of Periodontal Diseases in Humans

Chronic Periodontitis (localized/generalized)
Localized Aggressive Periodontitis (LAP)
Generalized Aggressive Periodontitis (GAP)
Periodontitis as a Manifestation of Systemic Disease
Associated with Hematologic Disorders
Associated with Genetic Disorders
Necrotizing Ulcerative Periodontitis
Combined Periodontic-Endodontic Lesions
Abscesses of the Periodontium
Armitage [1-3]
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Most patients who present with plaque-induced periodontitis will in fact possess
the chronic form of the disease [4-7]. The most likely presentation of a chronic
periodontitis patient is a patient greater than 30 years of age; gross plaque and
calculus, substantial gingival inflammation is present, deepened periodontal
pockets (> 3mm), and the presence of calculated periodontal attachment loss.
Generally speaking chronic periodontal disease is a slow continuously progressing
disease[8-10], but within this process may exist short periods of advancing rapid
attachment loss [11, 12]. Previously chronic periodontitis was given the misnomer
“adult periodontitis” since only the adult population was believed to be susceptible
to the disease. However, this has been shown to be false as a result of past and
more recent epidemiologic data clearly showing that chronic periodontal disease
can be present in younger populations [9, 13]. Although specifically chronic
periodontitis can be observed to occur in either localized or generalized
distributions within patients, these specific two forms appear to be vastly similar or
almost identical with regards to their presentation, pathogenesis, and progression.
Aggressive periodontitis, however, is far more rare than chronic periodontitis and
mainly affects children and adolescents. It also can occur in both localized and
generalized presentations, but unlike chronic periodontitis, these distributions
differ significantly with respect to their pathogenesis [4, 13]. Localized aggressive
periodontitis (LAP) and generalized aggressive periodontitis (GAP) were
previously called “localized and generalized juvenile periodontitis”, respectively
[14].
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Biofilms
These different presentations of periodontal diseases are best described as
multifactorial infections, which are elicited by the presence of an entire community
of complex of bacterial species. This community of organisms referred to as a
“biofilm” interacts with the host, specifically with connective tissue and immune
cells, which in turn causes a release of large number of pro-inflammatory cytokines
and chemokines. These pro-inflammatory mediators lead to the degradation and
destruction of cellular structures of the periodontal organ, namely: bone,
periodontal ligament, sulcular epithelium, and junction epithelium [15]. The trigger
for the initiation of periodontal disease is the presence of dysbiotic microbial
biofilms composed of bacteria that colonize the tooth surface in the sulcular region.
This region lies between the tooth surface below the cement-enamel junction and
the gingival margin and plaque formation is mediated through specific adherence
interactions and accumulation due to architectural changes in the sulcus [16]. The
characteristics of microbiological progression from periodontal health to gingivitis
(e.g. chronic inflammation of the gingival tissue without tissue destruction), and
eventually to periodontal disease are vast and complicated [17].

Although it has been previously estimated that out of nearly 1,000 different
microbial taxa are able to colonize, at least transiently the oral cavity of humans
and from a complex organized biofilm [18], it is still not fully understood how the
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multitude of different species exist and work harmoniously to begin the pathogenic
process and progress to full blown disease state. Previous studies have shown
that of the just under 1000 species detected in the oral cavity approximately 500
are found to be present in periodontal plaque [19]. Some of these organisms most
certainly are simply commensal or opportunistic species, but it is well documented
that certain species drive the pathogenicity of the bacterial plaque into more
virulent and destructive states [20]. Previous work has shown that even early
colonizers and previously deemed commensals such as Streptococcus gordonii
can have a profound effect on the pathogenicity of other organisms such as A.
actinomycetemcomitans and Porphyromonas gingivalis [21]. It has been shown in
several studies, and mentioned previously here that a multitude of bacterial
species call the human mouth their home, humans overall understand very little
about the consequences of harboring our bacterial inhabitants [22, 23]. Can the
presence of just one of the “bad guys” turn our whole “neighborhood” into a difficult
place to manage? Or does it take a combined effort of the community as a whole
to corrupt our own host defenses. With regard to other dental diseases, such as
dental caries, evidence is strong enough to allow us to point to the causative agent;
Streptococcus mutans and Lactobacillus sp. Since these species have been
identified, many papers have assessed the bacterial causative agents in patients
in the varying states of periodontal health, gingivitis, and periodontitis [17, 20, 22,
24, 25]. We are aware of a great many gram-positive bacterial species that serves
as beneficial commensal species and serve to help maintain important oral health.
We now also know that as the progression of the disease proceeds and heads
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further towards gingivitis and chronic periodontitis, greater numbers of gramnegative species begin to inhabit the sulcular epithelium and surrounding
dentoalveolar structures. More striking though, is the simple fact that there is still
no verifiable shown data, that one solitary species can solely cause the wideranging effects that periodontal disease can elicit in the mouth. No one organism
can account for the varied destructive processes that occur in the disease process.
This leaves us with the thought that the disease can only progress if several
bacterial species join forces and the signs and symptoms of periodontal disease
are in fact the result of a group effort. It must be clear then that a specific “consort”
or “complex” of bacterial species must trigger the transition from a state of oral
health to periodontal disease. Innumerable studies have focused on one specific
bacterial species responsible for signs and symptoms of periodontal disease, but
these do not account for the whole story. This, taken as a whole, supports the
notion that the effects from periodontal disease must be the result of consortia of
bacterial species acting as a complex biofilm to cause, elicit, and promote the
disease [24-27]. Recently there has been reassessment of the “roles” of several
bacterial species that are known to be involved in the progression of periodontal
disease. These organisms were routinely found in examinations of patients who
presented with periodontal disease and also in healthy controls. These species are
now even commonly referred to as periodontopathogens. Included in this group
are P. gingivalis, A. actinomycetemcomitans, T. forsythia, and T. denticola.
Influential studies by Socransky and Haffajee [24] used newer methodology of
stratifying these bacteria into their respective niches based on their roles within
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oral microbiomes in the disease process leading to change from health to disease
states.

Researchers organized the organisms into groups or “complexes”.

Individual complexes were based on the prevalence of the bacterial “affiliations”
with one-another, and corresponding complexes associations with health,
gingivitis, or periodontitis disease conditions [25-29]. These groups or complexes
of different microbes were also stratified according to the sequence of colonization
on the tooth surface in conjunction with periodontal disease severity. What
Socransky et al. [20] labeled as the ‘red complex’ contained bacterial species that
show up later in biofilm maturation phase. These bacterial species, namely, P.
gingivalis,

T.

denticola,

forsythus or Tannerella

and T.

forsythia (previous

forsythensis)

were

shown

names Bacteroides
to

be

effective

periodontopathogens [11, 20, 24, 26, 30]. In this same train of thought these
investigators also concluded that this “red complex” represents the pinnacle of
biofilm maturation and development and thus leading to advancing disease states.
Multiple other researchers have made note of this cooperation between species
within the same complex and between members of different complexes. A strong
association has been observed between T. forsythia and P. gingivalis found in
periodontal pockets in patients, whilst in fact P. gingivalis has not been detected in
the absence of T. forsythia within the periodontal pocket [31]. A strong relationship
between P. gingivalis and T. denticola was found whilst taking plaque samples
gathered in a study looking at diverse ethnic groups [32]. Moreover, constituent
members of the red complex were located in significantly higher percentages in
patients with periodontitis [33, 34] and also in probing sites with deeper pockets
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[35-40]. These separate bodies of work support the theory that no one single
bacterial species is etiologic for periodontal disease propagation or progression,
and periodontal disease is not a singular “bacterial infection” but instead that the
sum total of bacterial species in the oral cavity co-existing and co-habituating the
oral microbiome are required to initiate the onset of periodontal disease. How these
different species and organisms, as well as virulence determinants of the individual
bacteria, contribute to disease progression remains unclear. Another hypothesis
in more recent years has challenged the way we typically look at the “complexes”
of oral microbiota in the mouth. While looking at the red complex organisms one
would beg to ask the question, would higher numbers of these organisms correlate
with greater periodontal tissue destruction. In fact, certain pathogens, more
specifically, some from the red complex are actually found to be present in low
numbers. More recently, multiple analyses of the human microbiome have started
to shift the focus on biofilms away from consideration as a true “infection” but
instead as a dysbiotic disease. We are beginning to live in the age of the dysbiotic
inflammatory disease. Dysbiosis is a process by which communities of normally
healthy bacterial species become unstable and unregulated and in response drive
the inflammatory process. This outlook has become more optimal a term to assign
to periodontal disease than just giving few species the honor of being disease
causing agents. In healthy individuals, oral microbiota remains in a state of
harmony and regulation, but in susceptible individuals or compromised patients,
dysbiosis can lead to unfavorable and harmful host-microbial interactions and
eventually leads to periodontal inflammation and destruction of the periodontal
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tooth supporting structures [41-43]. This in turn leads to the inflammatory reaction
products being released into the gingival crevicular fluid (CGF) which then
promulgates and promotes furthering the disease process [44-46]. This cycle of
inflammation and dysbiosis could be a key factor that plays into periodontal
disease’s main components, its lasting effects and difficulty to treat. Traditional
therapy of scaling and root planning for periodontal disease, along with
debridement and maintenance of the oral cavity may now be possibly augmented
to include adjuvant therapies that target this dysbiotic shift towards more
pathobiont species [47, 48]. In addition to this potential benefit, some of released
host factors or molecules could have utility as disease markers in patient
treatment. This could serve to reflect a more accurate disease state or give a
better indication of the level of periodontal inflammation and disease progression
than was previously available by solely clinical examination [49].

The keystone pathogen hypothesis was posited as a result of new information
coming to light in the field. Studies showed that conversely, relatively low level of
the red complex species were actually present in biofilms, and in the mice bone
loss model suspected periodontopathogens were only needed in small numbers
to influence periodontal inflammation and bone loss [50, 51]. The small bacteria
cell count were enough to initiate a shift in the number and makeup of the complex
biofilm. This alteration of the biofilm composition occurred before the onset of
significant bone loss and was closely associated with the colonization of P.
gingivalis, indicating that the cause of the disease was the shift in bacterial species
10

composition or dysbiosis not solely the offending organisms’ presence alone [51].
This in conjunction with the observed fact that P. gingivalis, in the absence of other
commensal bacteria, fails to cause periodontitis in mice. For the purposes of this
dissertation, our discussion will focus mainly on the periodontopathogen and
keystone pathogen, P. gingivalis, its associated virulence factors, and the methods
by which these are manufactured and undergo post-translational modifications.
Poprhyromonas gingivalis
P. gingivalis, as mentioned above, has been a heavily studied pathogen in the oral
cavity and will be mainly the subject of this dissertation. As mentioned previously
we label this bacterium as a keystone pathogen in human periodontitis [50, 52]. By
placing this moniker on this bacterium, we imply that this organism is capable of
causing dysbiosis. The dysbiosis can manifest in the form of either relative number
or abundance of pathogenic species or change in the role or stratum of the species
within the biofilm, even at low microbial levels within the biofilm. Microbial analysis
studies have shown that despite its known importance in oral biofilm, P. gingivalis
is only a minor constituent of periodontal disease-associated biofilms [53-55]. This
is further confirmed by studies showing that, in a mouse model of periodontitis, P.
gingivalis was able to colonize in low-levels and was shown to cause an increase
in certain populations of the periodontal microbiota followed by inflammationdriven alveolar bone loss [51]. In addition, serving as a keystone pathogen comes
with certain responsibilities such as serving a specialized role in the biofilm
community. This role coordinates and modulates the activity of other organisms
within the plaque and plays an essential role in its pathogenicity [56, 57]. In this
11

role, P. gingivalis influences the transition from mainly commensal bacteria into a
pathogenic biofilm [52]. P. gingivalis is a Gram-negative, obligate anaerobe, and
asaccharolytic rod which possess a number of virulence factors [58-60]. Many of
these virulence factors are directly related to P. gingivalis’ ability to subvert the
host immune system. The use of these virulence factors is what makes P.
gingivalis an effective pathogen.
Gingipains
Some of these virulence factors alluded to previously are the proteases,
gingipains. Included in this category are the arginine-specific gingipains [Arggingipain-A (RgpA) and Arg-gingipain-B (RgpB)] and also the lysine-specific
gingipain [Lys-gingipain (Kgp)]. These are encoded respectively by their three
constituent genes within the P. gingivalis chromosome commonly referred here as
rgpA, rgpB and kgp which are heavily conserved among different clinical and
experimental strains of P. gingivalis [61]. The products of the translation of these
genes (specifically the rgpA and rpgB), RgpA and RgpB, both contain a caspaselike domain (that retains specificity for Arg-Xaa peptide bonds) and an
immunoglobulin-like domain. Uniquely in the proteinase RgpA, the protease and
Ig-like domain is subsequently followed-up with a large hemagglutinin-adhesin Cterminal extension. Closely related to the above protein, the kgp gene-translation
product, Kgp, contains a catalytic domain specific for Lys-Xaa peptide bonds and
also contains a hemagglutinin-adhesion domain not too unlike the rgpA translation
product. [62, 63], RgpB lacks the hemagglutinin-adhesin domains but the short Cterminal domain is conserved. Gingipain translation products undergo heavy post-
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translational modification. Nascent translation products encompass a profragment, a catalytic domain, an Ig-like domain, hemagglutinin-adhesion domains
(only in RgpA and Kgp) and the conserved C-terminal domain (CTD). During
secretion of RgpB, the pro-fragment is proteolytically removed and subsequent
processing of the CTD reveals the active catalytic domain followed by the Ig-like
domain. Subsequent glycosylation and incorporation to the outer membrane
surface occurs afterwards. In the case of RgpA and Kgp similar processing occurs
but the hemagluttanin-adhesin domains remain non-covalently associated with the
catalytic domain. Lastly, gingipains once processed are secreted either as a
monomeric form specific to the case of RgpB, or as complexes of protease and
hemagglutinin-adhesin domains in the case of RgpA and Kgp. These complexes
are either predominantly attached to the bacterial surface or released into the
medium in a soluble form. This is dependent on a P. gingivalis strain, for example
the strain HG66 secretes soluble gingipains freely into the media. Gingipain
activities serve as meditators for nutrient acquisition, serve to cleave receptors on
the host cell surface, and moreover, avoid and subvert the host immune system
by inactivation of cytokines and components of the complement system. One of
the most profound changes observed in patients with clinical periodontal disease
is the aberrant remodeling of the host periodontal tissues. Structural changes that
are often associated and observed with advanced periodontal disease include
alveolar bone resorption and periodontal ligament destruction. These changes in
structure in turn lead to attachment loss and periodontal pocket formation and
eventually tooth loss. Periodontal pockets found in patients with periodontal
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disease are also lined with epithelial cells that have had alterations, making them
distinctly different from healthy cells that form the junctional epithelium found in the
healthy periodontium. To accomplish this tissue-remodeling host cells require
proteolytic degradation of important structural elements and extracellular matrices
such as the collagen fibers forming the periodontal ligament and proteins involved
in cellular junctions and extracellular matrix proteins [64-67]. The mechanism by
which gingipains play a role in this process is complex and beyond the scope of
this introduction. But in summary gingipains are important both directly and
indirectly involved in the pathological tissue remodeling associated progressing
disease process of periodontitis. Nevertheless, it is most likely that gingipains are
not solely involved as the major virulence factor in periodontal disease tissue
destruction [59]. It is instead much more probably that these proteases synergize
with other mechanisms and virulence factors used by P. gingivalis and other
bacteria and disrupt the host proteolytic balance and interfere with endogenous
host protease inhibitors. Once this balance has been disrupted, host proteases,
namely MMPs, TIMPs, and neutrophil elastase, drive the response in the
periodontium for accelerated remodeling and pathological destruction of the host
tissues[64, 68]. The effects of gingipains have been studied in great details and
the role that they play in the disease process is expanding [59]. This variable output
of potent virulence factors gives P. gingivalis quite an arsenal with which to exert
effects into the host organism and biofilm community.
Protein Secretion Systems of Bacteroidetes Species
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Apart from the Sec pathway that exports proteins into or through the inner
membrane [69, 70], the armamentarium of well-characterized secretion pathways
of Bacteroidetes is surprisingly limited. Bacteroidetes possess both type 1 and type
6 secretion systems (T1SS and T6SS) that are responsible for secreting proteins
to extracellular environment bypassing the periplasm. Recently, there has been a
great deal of effort produced to characterize the T9SS. This system is typical for
Bacteroidetes and rarely, if ever, found outside the phylum [71, 72]. The T9SS
machinery transports proteins across the outer membrane, which were first
exported into the periplasm via the Sec translocon. All proteins secreted by T9SS
possess a characteristic C-terminal domain (CTD) that codes for transportation
through the outer membrane [71, 73]. The processes that are undertaken
upstream of CTD-dependent secretion have garnered less investigation, mainly
due to their ubiquity in other organisms and Bacteroidetes and have been
extensively studied in gram-negative bacteria in general [70]. We report here that
these upstream processes are unique to Bacteroidetes and do in fact merit
attention. To put this more into perspective, some background on the Sec
translocon is helpful.

The Sec pathway identifies target proteins by the presence of a signal peptide [74].
These signal peptides contain a tripartite architecture. They consist of a positively
charged N-terminal region, which is thought to designate proteins to the
phospholipid membrane, a hydrophobic region, which is hypothesized to be
inserted into the membrane, and finally a shorter region that often contains a
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consensus motif for a signal peptidase [75, 76]. Proteins that contain signal
peptides can escape from the Sec translocase in two different ways. If they
manage to escape “laterally”, they will then become contained within the inner
membrane [69]. The other way would have them reach the periplasm, but the
signal peptide portion is not cleaved and remains in the inner membrane. This
leaves the proteins’ C-terminal end (with a signal peptide cleavage site) exposed
on the periplasmic surface of the inner membrane [75]. The eventual fate of
proteins that reach this stage will depend on the type of the signal peptide
contained within.

Proteins that carry a type I signal peptide are released from their membrane
anchored signal peptide by signal peptidase I (SPI) [74, 75]. They will subsequently
remain in the periplasm, or if necessary be transported further, for example, by a
T9SS through the outer membrane, ultimately destined for the surface of the outer
membrane or for release into the environment [71]. Proteins which carry a type II
signal peptide undergo processing differently. A diacylglyceryl transferase (termed
Lgt) first attaches a diacylglycerol membrane anchor to the cysteine residue which
resides immediately downstream of the signal peptide [77]. Secondly, signal
peptidase II (SPII) (also known as lipoprotein signal peptidase or Lsp) can cleave
a lipoprotein upstream of the modified cysteine residue [78, 79]. Occasionally,
lipoproteins can remain attached to the inner membrane while others are
transported to the outer membrane via the Lol system [80]. Thus, lipoproteins
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found in gram-negative bacteria are generally periplasmic proteins which are
anchored either to the inner or outer membrane of the bacteria.

The N-terminal residue of proteins is frequently chemically modified, and these
modifications often have a signaling role. If an N-terminal glutamine residue is
exposed as a result of proteolysis, these glutamine residues have the capability to
spontaneously cyclize to pyroglutamate, with concomitant release of ammonia as
a side product. The reaction is also facilitated by inorganic catalysts such as
phosphate ions serving as the proton shuttle, and furthermore, can be catalyzed
enzymatically by glutaminyl cyclases (QCs) [81].

Glutaminyl Cyclase
As one of the enzymes for protein post-translational modifications, glutaminyl
cyclase (QC; glutaminyl-peptide cyclotransferase (QPCT), EC 2.3.2.5) is an
acyltransferase that catalyzes N-terminal pyroglutamate (pGlu) formation on
proteins or peptides and the concomitant release of ammonia or water molecules
see Figure 1 [82].
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N-terminal cyclization of glutaminyl peptides by QC.

Stephan Schilling et al. J. Biol. Chem.
2003;278:49773-49779
©2003 by American Society for Biochemistry and Molecular Biology

Fig. 1: N-terminal cyclization of glutaminyl peptides by QC. Glutaminyl containing
peptide is cyclized in the presence of QC by formation of an intermediate state that
culminates in the release of ammonia.
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The cyclization of L-glutamine into pyroglutamate is considered a quasiirreversible intramolecular acyl transfer reaction. The N-terminal peptide amino
group is responsible for a nucleophilic attack on the γ-carbon amide, forming a
tetrahedral intermediate. Subsequent decomposition of this intermediate occurs
from net 1,3-proton transfer from Nα onto a leaving ammonia, forming the pGlu
ring. This cyclization or modification appears to be involved in the structural
stability of secreted proteins, resistance to aminopeptidase degradation, and
hypothetically play an important role in mediating receptor binding [83]. QC is a
catalytically non-discriminatory enzyme; acting upon an availably N-terminal
glutamine residue, although it does exhibit slight preference for substrates
containing a penultimate bulky hydrophobic residue [84]. Recently it has been
shown that phosphate ions in conjunction with QC are able to operate as a
coordinated proton transfer system. This system is able to effectively increase the
rate of cyclization by QCs. Possibly; phosphate acts as a dual functioning acid–
base catalyst to increase the proton transfer rate, where simultaneous protonation
and deprotonation occur together in conjunction with a cyclic-ring transition state
(Fig. 2 A and B). Previously phosphate ions have been hypothesized to serve as
dual functioning catalysts during the iminolactone hydrolysis [85] or for thiamin
enzyme tautomerization [86]. Acid–base catalysis is the primary source of
catalysis used by QCs. The proposed role of the active-site zinc ion in QC can be
nicely correlated to the above-described rate-limiting trapping of T ± in acyl
transfer reactions in solution (Fig. 2 B). The active site zinc functions as a strong
Lewis acid, and proton transfer from the attacking α-amino group to the leaving
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ammonia is accelerated by a glutamic acid moiety in conjunction with two other
acidic residues, as suggested by QC crystal structures [87, 88].
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Fig. 2: Hypothetical role of phosphate (A and B) and QC (C) in acceleration of
glutaminyl cyclization. Phosphate ions facilitate the proton transfer onto the leaving
ammonia. The catalysis might involve facilitated proton transfer onto the oxanion
(A) or deprotonation of the attacking α-amino group (B). The proton transfer in QC
is facilitated by a glutamic acid residue. A significant acceleration of the reaction is
achieved by “trapping” of the oxanion by the active site zinc ion. Possibly, the
proton transfer from the attacking alpha-amino group to the leaving ammonia
occurs simultaneously [89].

QC was originally discovered in dried latex belonging to the Carica papaya (CpQC)
plant species [90]. Glutaminyl cyclases (QCs) have been demonstrated in multiple
plant and bacterial species and share a common ancestry [91-94]. It has been
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found that the known mammalian QCs are either Golgi-resident or freely secreted
enzymes [93]. Several peptide hormones and proteins carry N-terminal
pyroglutamyl residues. Until somewhat recently, the cyclization of L-glutamine
peptides’ N-terminus into pyroglutamate was thought to occur spontaneously [95].
This cyclization was shown that the conversion occurs under physiological
conditions but at a very slow rate, therefore necessitating the need for enzyme
catalysis [96]. Mammalian and plant QCs, however, have been discovered to serve
as this executor of the reaction [97-101]. In general, both mammalian and plant
QCs appear to have similar molecular masses, ~33 and ~40 kDa, respectively,
and both are monomeric proteins [102, 103]. The primary structures of the
proteins, however, display no sequence similarity, and the secondary structure of
the individual QCs are completely different. The plant CpQC and the related QC
from bacterial plant pathogen Xanthomonas campestris (XcQC) adopt a fivebladed beta-propeller fold [104]. As one would expect for beta-propeller proteins,
the active site is located near the propeller axis [105].. Mammalian QCs however
are shown to encompass an α/β-fold [106-108]. In addition, currently identified
plant QCs do not share sequence homology to other known plant enzymes, which
places them into a separate enzyme family or subfamily [100]. On the other hand,
identified mammalian QCs possess clear homology toward known bacterial
aminopeptidases, thus suggesting possible the evolutionary origin of the protein
family [107]. The mechanism of catalysis for plant QCs is much less clear than for
mammalian QCs. In mammalian QCs, the cyclization reaction serves its function
during maturation of numerous cytokines and neuropeptides in the secretory
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pathway, such as gonadotropin-releasing hormone (GnRH), thyrotropin-releasing
hormone (TRH), and monocyte chemotactic protein-2 (MCP-2). The theoretical
role of the pGlu residue on these peptides is believed to serve two functions; (1)
protecting the peptides from peptidase degradation and (2) providing the proper
conformation of the peptide to facilitate receptor binding [109, 110]. Uncontrolled
expression of QC in humans (HsQC) has been shown to be related to certain
pathological conditions, for example Alzheimer disease [111]. Site-directed
mutagenesis and X-ray crystallography studies of recombinant HsQC have given
us large amounts of information about the catalytic mechanism of QCs [112, 113].
Furthermore, HsQC has been used as a target for inhibitors, which have been
synthesized and developed as drugs to treat the relevant diseases that occur from
their overabundance [94, 114]. QCs have also been shown to be present in a
number of snake venom isolates [115] in keeping with finding that proteins and
toxins in snake venoms are often resistant to Edman-degradation during sequence
analysis. Cases that have been shown include bradykinin-potentiating peptides
[116, 117], metalloproteinase inhibitors [118], and endogenous metalloproteinases
[119]. Based on current literature, human QC is thought to share the scaffold of
known bacterial aminopeptidases [120]. This is in contrast to the fact that all the
putative QCs thus far identified in bacteria share homology with plant QC. When
analyzed by atomic absorption spectroscopy, HsQC has been shown to contain
one zinc ion per HsQC molecule [121]. Competitive inhibitors of HsQC have been
identified, such as heterocyclic compounds (imidazole, tetrazole, and triazole
rings). This is most likely due to nitrogen atoms serving as good coordinators of
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the active-site zinc ion found in QC [122, 123]. Solely the fact that HsQC could be
inhibited/inactivated by heterocyclic inhibitors suggests that the zinc ion located
within the QC is essential for catalytic activity [94]. In stark contrast, the same
heterocyclic chelators display no inhibition of plant QCs [103]. Considering this
information together, both plant and mammalian QCs are thought to belong to two
different enzyme families with different ancestral origins [100]. While mammalian
QCs are implicated in the maturation of numerous neuropeptides and cytokines,
such as thyrotropin-releasing hormone (TRH) and gonadotropin-releasing
hormone (GnRH) [102, 124, 125], the physiological function of plant QCs remains
poorly characterized. Recently, it has been suggested that plant QCs could be
involved in defense mechanisms [126, 127], a hypothesis that is supported by the
observation that the quantity of plant QC expressed increases greatly as a result
of repeated injury [127]. The role of QCs in both bacteria and parasites has not
been studied in depth. Advances in methodology for QC activity assays [128] and
the discovery of new HsQC inhibitors [114, 129] have rendered better tools to
explore QCs. A new QC has been isolated from P. gingivalis and its role has been
examined for the first time. Structural homology models of known QCs were
generated and compared. Furthermore, we successfully cloned and sequenced
the QC cDNAs from P. gingivalis and compared the sequence with that of human
and other animal QCs. In addition, we also examined the optimal pH range,
stability, and the effects of metal chelators, metal ions, and finally examined
specific QC inhibitors on the representative bacterial QC. These QCs share similar
catalytic activity but structurally remain distinctly different. [113, 126]
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In studying the proteome of P. gingivalis and its novel T9SS, protein sequences
destined for secretion via the T9SS with the conserved C-terminal domains (CTDs)
that facilitate secretion from through the outer membrane complex [73].
Approximately 30 CTD-bearing proteins exist in P. gingivalis genome and these
proteins all contain this conserved C-terminal domain [73]. Recently it has been
demonstrated that the CTD-containing proteins are secreted and attached to the
cell surface via the type IX secretion system (T9SS) [73, 130-132]. These CTDbearing proteins undergo extensive post-translational modifications before
attachment to the surface. Belonging to this group of CTD-containing proteins are
the gingipains (RgpB, HRgpA, Kgp), which are major virulence factors of this
periodontopathogen [133]. Upon examination of the sequences of these T9SS
cargo proteins it can be observed that a N-terminal Gln residue is present just after
the N-terminal signal peptide. Mass spectrometry analysis of these secreted
proteins revealed that after post-translational modification, a pGlu residue is
present at the N-terminus of the mature protein. This led us to hypothesize the
existence of a bacterial QC present in P. gingivalis, responsible for this cyclization
of Gln to pGlu. The presence of proteins containing N-terminal pyroglutamate
residues has been noted in previous proteomic studies on Bacteroidetes species
[73, 134-137]. At the outset of this study, we became aware of a drastic
overrepresentation of glutamine residues after SPI cleavage sites in P. gingivalis.
Starting from these two observations, we aimed to (1) clarify the pathway of
pyroglutamate formation, (2) determine the fraction of SPI substrates that could be
cyclized, (3) estimate the fraction that is actually cyclized, (4) test a possible role
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of pyroglutamate formation in sorting, initially for P. gingivalis only, and then for
Bacteroidetes in general, (5) characterize the function and importance of PgQC
within the T9SS. The function and purpose of the PgQC is hypothesized. In this
dissertation, we attempt to verify the existence, explain the purpose and role of QC
in P. gingivalis, and reveal its potential importance in the secretion pathway in P.
gingivalis and other Bacteriodetes.
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CHAPTER II: MATERIAL AND METHODS
Proteomes and taxonomy information were taken from UNIPROT [138]. Signal
peptides and cleavage sites were predicted using the batch version of
SIGNALP4.1 [139]. Lipoproteins were predicted using LipoP1.0 [140]. Sequence
logos were generated using the program Weblogo [141]. Intersections between
proteins with predicted signal peptide and predicted lipoproteins were using the
UNIX comm tool. Since not all UNIPROT species have been fully identified, some
species names such as “Tannerella sp.” were encountered.

Cloning, expression and purification of recombinant PgQC

The QC protein was expressed as a GST-tag fusion protein. Briefly, the entire
coding region of qc identified by BLAST search (PG_2157) was amplified from a
P. gingivalis W83 genome template with Platinum Taq DNA Polymerase High
Fidelity

(Invitrogen)

using

ATTAGAATTCATGAAAAGACTGATAACAACAGGAG

primers
and

F1_QC:
R2_QC:

ATTACTCGAGTCAGTGTGAAGCGGCTTTCACCTGTTCG. The 1001 bp PCR
product was digested with EcoRI – XhoI and cloned downstream in-frame with the
sequence encoding gluthatione S-transferase (GST), into EcoRI – XhoI digested
pGEX-6P-1 expression vector (GE Healthcare). Following confirmation by PCR,
resulting expression pGEX/QC vector was transformed into E. coli Bl21 (DE3)
expression host. Transformed E. coli cells were grown in LB media at 37° C until
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OD600 0.6, cooled down to 24 °C and expression of recombinant protein was
induced with 0.1 mM isopropyl-1-thio-β-galactopyranoside (IPTG). After overnight
cultivation, cells were harvested by centrifugation (6,000 x g, 20 min), resuspended
in PBS supplemented with lysozyme, and lysed by sonication (3 cycles of 10 x 3 s
pulses at 17 W). Cell lysate was clarified by centrifugation (30,000 x g, 30 min) and
loaded onto a pre-equilibrated glutathione-SepharoseTM High Performance
column. Recombinant GST-QC fusion protein was eluted using 50 mM Tris-HCl,
pH 8.0, supplemented with 10 mM reduced glutathione. The purified GST-QC
protein was subsequently incubated with PreScissionTM Protease (GE Healthcare)
and subjected again to chromatography on glutathione-SepharoseTM to remove
the GST tag. The purity of the resulting protein was verified by SDS-PAGE
electrophoresis (NuPAGER 4-12% Bis-Tris Gel, Invitrogen). Protein concentration
was determined by BCA Assay (Sigma).

PgQC activity assay

The activity of PgQC was determined essentially as previously described (33).
Briefly, 150 μl of the assay buffer (40 mM Tris-HCl, 400 mM KCl, pH 8.0), 10 μl of
chromogenic substrate (200 mM H-Gln-AMC in DMSO), and 10 μl of a
recombinant

bacterial

pyroglutamyl

aminopeptidase

(25

U/ml,

Unizyme

Laboratories, Hørsholm, Denmark) were mixed together in a microtitration plate
and preincubated 10 min at 30°C. The reaction was initiated by addition of 30 μl
appropriately diluted purified rPgQC or P. gingivalis whole culture or washed
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bacterial cells or subcellular fractions and after 1 min incubation the increase in
fluorescence (lex = 380 nm, lem = 460 nm) was recorded for 10-20 min at 30°C.
Unspecific cleavage of the H-Gln-AMC substrate was determined by omitting
pyroglutamyl aminopeptidase, the auxiliary enzyme. If necessary, the unspecific
cleavage was subtracted from PgQC activity. Metal-ion inhibition reactions were
carried out in similar fashion with each respective inhibitor added to the reaction
mixture prior to initiation of the assay.

P. gingivalis culture and cell fractionation procedures

P. gingivalis culture fractionation was performed at 4°C as described previously
[142] starting from stationary-phase (a 2-day-old) cultures adjusted to an OD600 of
1.5. Briefly, cells were collected by centrifugation at 6,000 × g for 15 min, washed
once with phosphate-buffered saline (PBS), and resuspended in 5 ml of 0.25 M
sucrose and 30 mM Tris, pH 7.6. After mixing gently for 10 min cells were
repelleted at 12,500 × g for 15 min. The outer membrane was disrupted by the
rapid addition of ice-cold distilled H2O and the spheroplasts were pelleted by
centrifugation at 12,500 × g for 15 min. The supernatant was designated the
periplasmic sample. The remaining spheroplast pellet was resuspended in 5 ml
PBS and ultrasonicated in an ice-water bath. Cellular debris and membranes were
pelleted by ultracentrifugation at 150,000 × g for 1 h, and the supernatant was
designated the cytoplasmic sample. The remaining pellet was washed and
resuspended in cold PBS by sonication.

29

This fraction was designated the

membrane sample. For individual membranes separation washed collected cells
were lysed by ultrasonication as described above. The membranes were pelleted
by ultracentrifugation (150,000 × g, 1 h) washed with PBS to remove periplasmic
and cytoplasmic proteins and resuspended in PBS by sonication. The inner
membrane was dissolved with Sarkosyl (lauryl sarcosine) and the residual
Sarkosyl-resistant outer membranes (OM) were pelleted by ultracentrifugation
(150,000 × g, 1 h). The supernatants were designated the IM samples while
pellets washed and suspended by sonication in PBS were designated the OM
samples. Purity of the various fractions was checked by Western blotting for ALPS or gingipains and the biotin containing 15 kDa biotin carboxyl carrier protein
(AccB alias MmdC or PG1609) as OM and IM specific markers, respectively [62,
143] (data not shown).

Generation of P. gingivalis ΔRgpB deletion mutant

For subsequent analysis, generation of plasmids suitable for rgpB gene
mutagenesis the pRgpBall master plasmid was first engineered based on the
pURgpB-E construct [142]. A partial rgpB gene section upstream of the
erythromycin cassette was replaced with whole rgpB coding sequence, together
with an 817 bp fragment containing its potential promotor. The new fragment was
amplified with primers RgpBall_F and RgpBall_R using genomic DNA of P.
gingivalis W83 and ligated into the linearized pURgpB-E plasmid (with EcoRI and
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SmaI restriction enzymes) by the Gibson’s method [144] resulting in pRgpBall-erm
plasmid. All primer sequences are listed in Table 2.

pRgpBall-erm plasmid
RgpBall_F
RgpBall_R
pRgpBdel-erm plasmid
RgpBQ1N_Rs
RgpBdelFs
RgpBdelRt
RgpBdelFt
RgpBQ24N mutation
RgpBQ1N_Fs
RgpBQ1N_Ft
RgpBQ1N_Rs
RgpBQ1N_Rt
RgpBQ25A mutation
Q25AF
Q25AR
pNRgpA-tet plasmid
RgA_Up_F
RgA_Up_R
RgpA_Dw_F
RgpA_Dw_R
Tet_BamHI_F
Tet_SalI_R
puc_EcoRI_R

GACGGCCAGTGAATTCTTAACCAT
GCTGTGGTGACGAG
AGCGGAAGCTATCCCAACAGTCT
CTTGGCGTAGTGCCAA
AACGCCATTCCTCCCAACAG
GGGATAGCTTCCGCTATTGCT
GGGTCTGCCGGCTGTGCAAACGC
CATTCCTCCCAACAG
TGCACAGCCGGCAGACCCGGGAT
AGCTTCCGCTATTGCT
CGGTCGCAACCCACAAGTAC
TGCAAACCCGGCAGAGCGCGGTC
GCAACCCACAAGTAC
AACGCCATTCCTCCCAACAG
CGCTCTGCCGGGTTTGCAAACGCC
ATTCCTCCCAACAG
GGAATGGCGTTTGCAGCTCCGGC
AGAGCGCGGTC
GACCGCGCTCTGCCGGAGCTGCA
AACGCCATTCC
GCCAGTGAATTCGGTCAGAGAGC
CGA
CGTTGTGGATCCTGAGCGTACCAT
ATCTTTTAACC
TTGGCAGTCGACTCGAGGAGCTG
ATTGGCTT
TACGCCAAGCTTGAGGAGCAGCA
ATTG
TCAGGATCCACAACGAATTATCTC
CTTAAC
CGAGTCGACTGCCAAGTTCTAATG
CTTC
ACCGAATTCACTGGCCGTCGT
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puc_HindIII_F
RgpAQ25N mutation
RgpAQ1N Fs
RgpAQ1N Ft
RgpAQ1N Rs
RgpAQ1N Rt
pNKgp-cep plasmid
Kg_Up_F
Kg_Up_R
Kg_Dw_F
Kg_Dw_R
CepA_F
CepA_R
pUC_BamHI_F
pUC_SphI_R

CTCAAGCTTGGCGTAATCATGGT
ACGCAATCCGAATGTGAGATT
GAACCAGACAGAGTTGGGACGCA
ATCCGAATGTGAGATT
GCAAATGCCATTCCTCCTAAT
CCCAACTCTGTCTGGTTCGCAAAT
GCCATTCCTCCTAAT
AGCTTGCATGCACACACCCCGAT
ATGGAAGCTTAAGTCAGTCCAGC
ATGAGGAAG
ACTTGAGATCTTAACCTTGGTCTG
CTCTAC
CCGGGGATCCTTCTACCGTAACGT
C
GACTTAAGCTTCCATAGACGATGC
CACACTG
GTTAAGATCTCAAGTCACCGATAG
TGATAGTG
TAGAAGGATCCCCGGGTACCGAG
CT
TGTGTGCATGCAAGCTTGGCGTAA
TCAT

KgpQ20N mutation
KgpQ1NFs
KgpQ1NFt

CTTGATGCTCCGACTACTCGA
AATAGCGCCAAGATTAAGCTTGA
TGCTCCGACTACTCGA
KgpQ1NRs
GGCGTAAAGACCAACTCCCA
KgpQ1NRt
CTTAATCTTGGCGCTATTGGCGTA
AAGACCAACTCCCA
Table 2: Primers used for construction of plasmids for P. gingivalis mutagenesis.

Next, the RgpB deletional plasmid (pRgpBdel-erm) was obtained by the truncation
of pRgpBall-erm plasmid using the PCR based Site-directed, ligase-independent
method (SLIM) [145] with primers listed in Table 2. With this approach, only the
small fragment of 3’ (154 bp) of rgpB CDS was preserved on the pRgpBdel-erm
plasmid. The ΔRgpB strain was obtained in the homologous recombination event:
the plasmid was elecroporated into the P. gingivalis W83 strain and the positive
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recombinant clones were selected with 5 µg/ml erythromycin. Proper
recombination was verified by sequencing.

Generation of P. gingivalis gingipains Q mutants

Mutagenesis of each gingipain required a dedicated master plasmid. For RgpB
studies the pRgpBall-erm construct was used. The Q1N mutation (replacement
CAG codon into AAC) was incorporated using the SLIM method (resulting in the
pRgpBallQ1N-erm plasmid), the Q25A mutation (replacement of the CAG codon
into GCT) was introduced by the QuikChange method (Stratagene) (generating
pRgpBallQ25A-erm), all sequences of applied primers are listed in Table X in the
RgpBQ1N section. These plasmids were introduced into the P. gingivalis W83
RgpA-C strain lacking the whole rgpA gene [142] by the electroporation and the
recombined clones were selected with 5 µg/ml of erythromycin. The obtained
strains

were

partially

sequenced

and

named

ΔRgpA/RgpBQ25N

and

ΔRgpA/RgpBQ25A, respectively.

For RgpA mutagenesis, a master plasmid pNRgpA-tet was engineered. Two DNA
fragments were amplified from P. gingivalis genomic DNA. The upstream 915 bp
fragment consisting of sequence directly adjacent to the RgpA promotor was
amplified with primers RgpA_Up_F and RgpA_Up_R). A downstream 2835 bp
fragment, comprising the 5’ sequence of the RgpA gene together with 388 bp of
its proposed promotor was amplified with primers RgpA_Dw_F and RgpA_Dw_R.
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The tetracycline (tetQ) resistance cassette was amplified from the pT-COW
plasmid [146] with primers Tet_BamHI_F and Tet_SalI_R. The backbone, the
pUC19 plasmid, was linearized by PCR reaction with primers puc_EcoRI_R and
puc_HindIII_F. All four amplified fragments were combined in the single step
reaction by the method described by Gibson [144]. The Q24N mutation
(replacement cag codon into aac) was incorporated to the construct with the SLIM
method. Sequences of applied primers are listed in Suppl. Table 1 (RgpAQ24N
section). This plasmid was introduced into the P. gingivalis W83 ΔRgpB strain
lacking the whole rgpB gene by the electroporation and the recombined clones
were selected with 1 µg/ml of tetracycline. Obtained strain was partially sequenced
and named RgpBdel/RgpAQ24N. The non-mutated master plasmid was also
introduced into the ΔRgpB strain P. gingivalis W83 and the unaffected expression
and activity of RgpA was observed.

For Kgp mutagenesis, the pNKgp-cep master plasmid was created in a similar
manner. First, two fragments adjacent to the start of the hypothetical Kgp promotor
were amplified from the genomic DNA, the 809 bp upstream fragment with
Kg_Up_F and Kg_Up_R primers, while the 3271 bp downstream fragment with
Kg_Dw_F and Kg_Dw_R primers. The beta-lactamase gene cepA was amplified
with primers CepA_F and CepA_R from template synthetized by the Life
Technologies based on the sequence deposited under AAA21538.1 number
(Gene Bank). The pUC19 plasmid was linearized with primers pUC_SphI_R and
pUC_BamHI_F. The Q20N mutation (replacement caa codon into aat) was
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incorporated to the construct with the SLIM method. Sequences of used primers
are listed in Suppl. Table 1 (KgpQ20N section). This plasmid was introduced into
the wild type P. gingivalis W83 by the electroporation and the recombined clones
were selected with 2 µg/ml of ampicillin. Obtained strain was partially sequenced
and named KgpQ20N. As a control, the non-mutated master plasmid was also
electroporated into the P. gingivalis W83 strain and the unaffected expression and
activity of Kgp was observed.

35

Fig 3: P. gingivalis mutant strains. A) schematic representing RgpBdel-erm. B)
RgpA-tet C) Kgp-cep. Schematic representation of steps undertaken to generate
P. gingivalis mutant strains.

Gingipain activity assay

The amidolytic activities of Rgp and Kgp enzymes were assessed by the hydrolysis
of the chromogenic substrate benzoyl-L-arginine-p-nitroanilide (BApNA) and
carboxybenzoyl-L-lysine p-nitroanilide

(zKpNA;

Novabiochem,

Germany),

respectively. In a 96-well format, 20-μl samples were preincubated in assay buffer
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(200 mM Tris-HCl, 100 mM NaCl, 5 mM CaCl2 [pH 7.6][71], supplemented with
fresh L-cysteine to 10 mM) for 2 min prior to the addition of 1 mM substrate in a
total volume of 200 μl. For activity measurement of Sarkosyl-treated membrane
fractionations (see Materials and Methods), a 0.125 mM concentration of a
synthetic

arginine

substrate

pyro-glutamyl-glycyl-L-arginine-p-nitroanilide

(pyroEGRpNA; Pharmacia-Harper, Uppsala, Sweden) was used instead of BApNA
due to precipitation of the BApNA substrate in the presence of the Sarkosyl
detergent. The presence of 0.1% Sarkosyl detergent in the assay did not affect the
rate of substrate hydrolysis as determined with purified RgpB (data not shown).
The rate of formation of p-nitroanilide was measured at 405 nm using a
SpectraMax Plus spectrophotometer (Molecular Devices Inc., CA). For ease of
comparison between mutants and statistical analyses of independent repetitions,
activity units were defined as the total activity present in the RgpB+ control mutant
culture equaling 100 U for culture partitioning studies, the total activity in the
RgpB+ control mutant cells equaling 100 U for cellular fractionation studies, or the
total activity in the RgpB+ control mutant membranes equaling 100 U for
membrane fractionation studies.

In vivo QC specific inhibition

Each inhibitor was dissolved in DMSO at 10mM and 100mM concentrations. Five
ml of a stock culture of P. gingivalis was equilibrated to OD600 = 0.1 in 3 separate
sealed tubes of 5ml of eTSB media (experiment repeated in triplicate). These tubes
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are of the correct diameter to be read using the spectrophotometer cuvette reader.
At inoculation either inhibitor concentration of 100µM or 1mM final concentration
(DMSO content ≤ 1%) was added or equivalent DMSO ≤ 1% alone. Inoculated
cultures of P. gingivalis were subsequently placed in an anaerobic chamber.
Samples consisting of 1.0ml of bacteria were retrieved at 2, 5, and 8 hours postinoculation. Samples were then centrifuged, supernatant was decanted, cell
fraction was washed twice with PBS to remove unbound excess inhibitor. Bacterial
pellet re-suspended in 300µl PBS and lysed by sonication (3 pulses, 5 s/pulse).
Eighty µl of lysate used for continuous spectrophotometric assay of glutaminyl
cyclase as previously described.

Affinity purified anti-QC Antibodies

CNBr-activated Sepharose 4B (GE Healthcare Lot # 10039621) was prepared
according to manufacturer’s specifications. CNBr-activated Sepharose 4B is a preactivated resin using the cyanogen bromide method, which couples antibodies or
other large proteins containing -NH₂ groups to the Sepharose media, without an
intermediate spacer arm. rPgQC was dissolved in coupling buffer (0.1 M NaHCO3
containing NaCl 0.5 M) at 5mg/ml of CNBr gel. CNBr beads were washed and
swelled on a sintered glass filter. rPgQC protein solution mixed with swelled gel
suspension in an end-over-end mixer for 2 hours at room temperature or overnight
at 4°C. Remaining active groups were blocked by addition of blocking agent 1.0
M ethanolamine or 0.2 M glycine at approximately pH 8.0 (2 hours at room
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temperature or overnight at 4°C). Excess protein was washed away by at least 3
alternating washes of coupling buffer and acetate buffer (0.1 M pH 4.5 containing
0.5 M NaCl). Blocking agent was removed with 3-4 washes of coupling buffer
followed by storage buffer (PBS containing preservative NaN3). Serum passed
through 0.45µm filter prior to application to the column. Serum was loaded into the
column, column washed with PBS until A280 reached baseline. The antibody bound
to the column is eluted with 0.1M Glycine-HCl, pH 2.8. Fractions collected into
tubes containing 1.0M Tris pH 8.0, to neutralize the eluted antibody. Antibody
fractions were pooled and dialyze vs. PBS and finally concentrated. ELISA was
run on serum, flow-thru, and eluate (Fig. 4).

39

Fig 4. Specificity of anti-QC antibodies. A 2-fold serial dilution afterwards was
continued until no detection using both Western Blot and ELISA, Western blot (left
panel and Elisa (right panel). ELISA titration was preformed using clear bottom 96well plate. Affinity purified QC concentration was determined by BCA assay at 1/10
dilution to be =8.4mg/ml. Concentration of QC was used @ 0.84mg/ml for first
dilution (1/512). A 2-fold serial dilution afterwards was continued until absorbance
was no longer detectable at 450nm wavelength.

SDS-PAGE and Western Blots
Samples were analyzed using established protocols ([133]). Samples were first
boiled in non-reducing SDS-PAGE sample buffer containing 2mM TLCK for 5 min
to inactivate all gingipains prior to the addition of 1% β-mercaptoethanol and boiled
for a further 5 min for complete denaturation. Samples were centrifuged briefly at
13,000 × g, 1 min to remove particulates and the supernatant separated on SDSPAGE and gels were stained with Coomassie Brilliant Blue. For Western blot
analysis resolved proteins were subsequently electrotransferred onto 0.22-μm40

pore-size nitrocellulose membranes and blocked in 2% BSA/PBS solution
overnight. RgpB was detected using a 1:2000 dilution of anti-RgpB mouse mAb in
TTBS (20mM Tris, 500mM NaCl, pH 7.5 supplemented with 0.1% Tween 20) for
3 h. Membranes were washed four times with TTBS before being probed for 2 h
with a 1:2000 dilution of an alkaline phosphatase-conjugated rabbit anti-mouse
polyclonal secondary antibody (Dako Cytomation, Denmark). Development was
carried out using the AP Conjugate Substrate kit as per manufacturer’s instructions
(Bio-Rad Lab., CA, USA). The in vivo PgQC and recombinant PgQC was detected
using a 1:100,000 dilution (1μg ml−1) of affinity purified specific (previously
described) anti-QC rabbit polyclonal antibody in 5% (w/v) skim milk/TTBS solution.
Membranes were washed four times with TTBS before being probed for 1 h with a
1:40,000 dilution of an HRP-conjugated rabbit anti-mouse polyclonal secondary
antibody

(Sigma-Aldrich).

Development

was

carried

out

chemiluminescent protocol according to manufacturer’s specification
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using

the

CHAPTER III: RESULTS AND DISCUSSION

Bacteriodetes SPI substrates typically have a Qln (Q) downstream of the SPI
cleavage site

The starting point for this study was the observation that many secreted P.
gingivalis proteins with a predicted signal peptide also had a glutamine (Q) residue
immediately downstream. The generality of this observation was confirmed on a
genome-wide basis using the batch version of SignalP (for gram-negative
bacteria). These species designations were pooled into “superspecies” groups,
with particularly well-defined Q-values, and an anomalously large number of
predicted proteins with predicted signal peptides or type I signal peptides. In none
of the analyzed species groups, the “superspecies” exceded 15% with exception
of Cyanobacteria, where 31% species were incompletely designated, often without
clear signs that several species were pooled (judging from the number of proteins).
Including the “superspecies”, 337 Bacteroidetes species, 13 Chlorobi species, 59
Spirochaetes species, 13 Chlamydia species, and 82 Cyanobacteria species were
analyzed. The number of proteins with predicted signal peptides was above 50 in
all analyzed species, guaranteeing that incomplete proteomes did not have a major
influence on Q-values. The medium number of proteins with predicted signal
peptides was 399 for the Bacteroidetes, 125 for Chlorobi, 163 for Spirochaetes,

42

128 for Chlamydiae, and 195 for Cyanobacteria. Removal of lipoproteins from the
set of proteins with predicted signal peptides was a relatively “small correction”.
The median values of the number of proteins with predicted type I signal peptides
per species were 299 for the Bacteroidetes, 104 for Chlorobi, 146 for Spirochaetes,
112 for Chlamydiae, and 161 for Cyanobacteria. As lipoproteins have a C after the
SPII cleavage site, their removal always increased predicted species Q-values. A
“Q” immediately downstream of the signal peptide was predicted in about half of
the cases. In the remaining cases, the residue after the signal peptide was
frequently a cysteine, suggesting that these proteins were lipoproteins/SPII
substrates. We used LipoP to identify and remove these proteins from the set. In
the remaining set, which should only contain SPI substrates, the fraction of
proteins with a Q after the SPI cleavage site exceeded 60%. Additional manual
checks, including checks with earlier versions of the SignalP program, suggested
that the true fraction of SPI substrates with a Q directly after the cleavage site may
be even higher (Fig 5).
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Fig. 5: Q-Value distribution in Porphyromonas - Fraction of predicated secreted
proteins with a glutaminyl residue immediately downstream of the SPI cleavage
site (Q-value) for different Porphyromonas species. Light gray bars indicated
predictions on SignalP alone, while the dark bars indicate the predictions after
removal of predicated lipoproteins (identified by LipoP)

The enrichment of glutamine downstream of the SPI cleavage site did not appear
to be specific for the proteins of a particular cellular compartment. CELLO [147]
predictions identified SPI substrate proteins in the inner membrane, the periplasm,
the outer membrane, and the extracellular space. In all compartments, the fraction
of SPI substrate proteins with a Q immediately downstream of the SPI site was
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48% or higher (Table 3), clearly indicating that Q enrichment was not characteristic
for proteins of a specific compartment. Placement of some SPI client proteins in
the cytoplasm by the CELLO server suggests that some predictions are in error.
Even with this reservation, Q enrichment does not appear to be characteristic for
SPI client proteins in a particular compartment. This conclusion was further
strengthened by the inspection of protein lists.

Table 3: CELLO Predictions -

Proteins with or without Q residue in P1’

downstream of a type I signal peptide according to their localization, predicted by
CELLO program.

Recombinant P. gingivalis PG2157 has QC activity and resides in the inner
membrane

The high frequency of newly exposed Q residues in SPI substrates in P. gingivalis
and the previously reported detection of 7 P. gingivalis proteins with N-terminal
pyroglutmate [134] suggested that glutamine cyclization might not be
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spontaneous, but enzymatically catalyzed. A BLASTP query of the P. gingivalis
proteome with the human QC sequence suggested that PG2157 (also called
PG_RS09565) may have QC activity. The recombinant protein (without a signal
peptide) did not exhibit aminopeptidase activity on any of the commercially
available substrates of general formula NH2-L-Xaa-pNA or NH2-L-Xaa-AMC.
However, it efficiently converted the fluorogenic substrate L-glutaminyl-AMC into
its respective pyroglutamic acid derivative (Km = 0.473 mM, kcat = 0.356 s-1, kcat/Km
= 1.34 mM-1s-1). We therefore refer to PG2157 (PG_RS09565) as PgQC and to
the recombinant version of the protein as rPgQC. SDS-PAGE of purification of
rPgQC shown in Fig. 6.
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SDS-PAGE of rPgQC Purification
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Fig. 6: Purification of rPgQC. SDS-Page of different stages of expression and
purification of recombinant P. gingivalis QC in E. coli BL21. Lane 2: Initial
bacterial lysate applied to column. Lane 3: Flow through of unbound proteins.
Lane 4: The fraction of bound recombinant protein plus the binding domain
containing PSP cleavage sites and HIS-tagged region. Lane 5: Processing of the
binding domain from the mature protein. Lane 6/7: Separation of the binding
domain from the rPgQC. Lane 7: Final sample after reapplication on NiSepharose column to further remove binding domain. Gel electrophoresis was
completed using 10 µl of respective sample and run according to established
protocol. (See Materials and Methods)
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Table 4: rPgQC Enzyme Kinetics
Michaelis/Menton kinetic parameters showing that, indeed, rPgQC is a glutaminyl
cyclase with much lower affinity for H-Gln-Xaa-Xaa than human or murine QC
α

(Determined in our lab) β([108]) γ([94]) δ([92]) ε([83])

Sequence analysis of PgQC revealed a canonical signal peptide with the typical
lipobox (Leu-Ser-Ala-Cys), suggesting that PgQC is a lipoprotein. Lipoproteins are
translocated across the inner membrane via the Sec system, and initially anchored
to the inner membrane by covalent attachment of a lipid anchor to the cysteine
residue, followed by signal peptide cleavage, and typically second N-acetylation.
Some, but not all lipoproteins are subsequently transferred from the inner to the
outer membrane. Therefore, we expected that PgQC should be anchored in the
inner or outer membrane.
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In order to determine QC localization experimentally, cell extract (CE) of P.
gingivalis in late exponential/early stationary phase of growth was fractionated into
cytoplasm and periplasm (CP), total membranes (M), outer membrane (OM), and
inner membrane (IM). The purity of the membrane fractions was verified by the
exclusive presence of the biotin-containing 15-kDa biotin carboxyl carrier protein
(AccA alias MmdC or PG1609) and gingipains in the IM and OM, respectively [136]
(data not shown). QC activity of the fractions was then measured using the
enzyme-coupled assay already used previously to demonstrate the activity of the
recombinant enzyme. QC activity was found in the IM and in fractions containing
IM (CE and M) but not CP and OM (Fig. 7A) clearly indicating that PgQC is
anchored in the inner membrane. This localization was further confirmed by
Western blot analysis of enriched subcellular fractions using rabbit polyclonal
antibodies anti PgQC (Fig. 7B).
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PgQC Subcellular Localization
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Fig. 7: PgQC is an Inner Membrane Protein. P. gingivalis in the early phase of
growth was fractionated into sub-cellular fractions including, whole lysed cell
extract (CE), cytoplasm (CP), membranes (M), outer membrane (OM), inner
membrane (IM), and QC activity was measured in each sample results given in
activity FU/s/µg. The QC activity in each fraction was determined with L-Gln-AMC
as a substrate using a coupled assay with pyroglutamyl aminopeptidase as an
auxiliary enzyme. The activity is shown as RF/s. The presence of PgQC antigen in
fractions was determined by western blot.
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Porphyromonas gingivalis QC is a zinc metalloenzyme

Previously, the metal ion content of human QC was unclear. Schilling et
al. proposed that human QC is a metalloenzyme based on the inhibition by several
metal ion chelators and the reactivation of apoenzyme by the subsequent addition
of zinc ions [92]. However, Booth and co-workers reported lower than 0.3 molecule
zinc ion per hQC molecule which was shown by mass spectrometry [120]. Because
neither the accessory enzyme for the reaction, pyroglutamyl aminopeptidase, nor
glutamic acid dehydrogenase, is inhibited by imidazole within the concentration
range used, both the fluorimetric and spectrophotometric assay were well adapted
for our purposes. The fluorimetric activity assay data (Table 5) revealed inhibition
by imidazole. Imidazole completely blocks substrate conversion by binding in the
active site. Inhibition of the enzyme occurs by removal and chelation of the metal
ion required for catalytic activity, leaving an inactive apoenzyme. 1,10Phenanthroline has been shown to mainly target zinc metallopeptidases and the
inhibition of QC by 1,10-phenanthroline has been previously described [99]. EDTA
has been shown under certain conditions to have an activating effect on QC
catalysis and our data confirms that small amounts display an activating effect. It
has previously been suggested that inhibition by phenanthroline is not due to metal
chelation [94]. Also, in addition to being inhibited by 1,10-phenanthroline, P.
gingivalis QC-catalyzed substrate cyclization was abolished in presence of
dipicolinic acid, another inhibitor of metalloenzymes. Both chelators inhibited QC
in a concentration and time-dependent manner, i.e. initial activity that was already
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inhibited was found to be further reduced after prolonged incubation with the
compounds (Fig. 8). However, EDTA did not show remarkable inhibition of P.
gingivalis QC until the concentration was increased almost to 2.0 M P. gingivalis
QC was almost completely inactivated addition of 5 mM 1,10-phenanthroline.
Schilling et al. have previously shown that repeated dialysis with chelator-free
buffer, human QC activity was partially reactivated up to 50–60% but only in the
presence of EDTA [94].

Table 5. Attenuation of rPgQC activity by reducing agents and imidazole.
Reactions were carried out at 30 °C in 0.06 M acetic acid, 0.06 M Mes, and 0.12
M Tris adjusted to the respective pH by the addition of NaOH or HCl. Data shown
as residual activity set as 100% for given reaction without inhibitor. Data points are
averaged triplicates.
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Effect of Chelators
Percent Activity
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EDTA
Orthophenantroline
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Fig. 8: Concentration dependent inhibition by 1,10-phenanthroline and EDTA
Percent residual activity of QC in the presence of either compound was determined
directly after the addition or pre-incubation of QC with each respective reagent for
15 min at 30 °C

To confirm effect of ionic strength on the activity of rPgQC, activity assay buffer
was supplemented with differing concentrations of NaCl and KCl. rPgQC activity
saw a sharp drop in activity with the addition of ion salts, but then activity tapered
off to around 50% activity as the concentration of ion salts increased dramatically.
(Fig. 9)
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Effect of Ionic Strength
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Fig. 9: Effect of differing concentrations of ionic salts on rPgQC activity.
Activity using continuous fluorimetric assay displayed as percent activity of QC
without ionic salts present in the activity assay buffer.

Sensitivity of the QC reaction to metal ions was also probed. Using the continuous
fluorimetric assay, a reaction mixture was pre-incubated with the respective ion
salt. Out of tested divalent cations only Cu2+ exerted strong inhibitory activity
(Table 6). Other metal ions had only slight effect only at 10 mM concentration in
the reaction mixture. Interestingly but not surprisingly, increasing Zn2+

54

concentrations within the QC assays (0.1 mM and higher) considerably reduce QC
activity, and this has been observed in previous studies [94, 123].

Table 6: Residual activity of rPgQC in the presence of competing metal ions.
Given as percent activity of rPgQC standard. Performed on 96-well plate in
triplicate, experiment repeated in triplicate. Values represent mean of the different
results.
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Pyroglutamate is present in signal peptidase I substrates

In order to experimentally demonstrate pyroglutamate at the amino-terminus of
SPI substrates, previously determined mass spectrometry data was re-analyzed
for P. gingivalis outer membrane vesicles [73, 136]. Outer membrane vesicles
(OMVs) are continuously shed. Their vesicle lumen (VL), vesicle membrane (VM)
and vesicle surface (VS) fractions contain proteins that are derived from the
periplasm, the outer membrane, and extracellular proteins anchored to the outer
membrane surface, respectively [148]. Pyroglutamate was inferred from the mass
of the identified peptide, which is 17 Da less than what the unmodified peptide,
and also by the fragmentation (MS/MS) pattern of the peptide. The MS/MS spectra
of these peptides indicate that the -17 Da modification is present near the Nterminus of each peptide, most consistent with pyroglutamate formation.
Altogether 27 proteins, all putative SPI substrates, with N-terminal pyroglutamate
were identified. Interestingly, no semi-tryptic peptides with N-terminal glutamine
were found in the entire P. gingivalis dataset, suggesting widespread
pyroglutamate formation, despite the incomplete evidence for the complete set.

In order to further confirm this conclusion, we compared sequences around the
cyclization site (and thus the SPI cleavage site) for proteins that were
experimentally identified, had a glutamine after the predicted SPI cleavage site,
and for which evidence for pyroglutamate formation was either available or not.

56

The region upstream of the SPI cleavage site, normally not expected to influence
QC, was included in the comparison in case SPI and QC may act together and QC
preferences may be influenced by SPI preferences. However, we did not detect
clear differences in the sequence logos of the two groups of proteins on either side
of the critical Q residue, further supporting the conclusion that QC acts broadly and
is not limited in its activity by specificity for residues adjacent to the substrate
glutamine residue (Table 7). Also noted is the fact that proteins with experimental
evidence for pyroglutamate formation at the N-terminus were present in all
compartments of outer membrane vesicles, this would subsequently stand against
a role in partitioning proteins between VL, VM or VS of OMVs or the equivalent
periplasmic space, outer membrane and outer membrane surface that these
proteins stem from (Table 7).
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Table 7: Q-value. Proteins from these compartments stem from the periplasm, the
outer membrane, and the outer membrane surface, respectively. The row “Total”
indicates the number of localized proteins, the row “Q” the number of proteins with
a Q exposed by SPI signal peptide cleavage (according to a prior manual
annotation, not focused on pyroglutamate formation), the row “SIGNALP = Y the
number of proteins with signal peptide, and the row “SIGNALP = Y&Q” the number
of such proteins exposing a glutamine after signal peptide cleavage. The row “pGlu
detected” identifies the number of proteins with experimentally verified
pyroglutamate. In very few instances, a pyroglutamate was detected in a protein
not predicted to expose a glutamine after signal peptide cleavage due an
erroneous SIGNALP prediction.
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Q downstream of the SPI cleavage site affects RgpA, but not RgpB and Kgp
secretion

In order to confirm that pyroglutamate formation does not affect secretion, we
needed a model system in which pyroglutamate formation does not influence
protein stability by controlling resilience against aminopeptidases. Gingipains
RgpA, RgpB and Kgp, the major proteolytic virulence factors of P. gingivalis, are
good model systems in this respect. The proteins are initially expressed as
preproproteins, and their type I signal peptides are then cleaved upon import into
the periplasm, exposing N-terminal glutamine residues. The CTD-domain
containing proteins are then exported further by the type IX secretion system
(T9SS). Upon secretion from the periplasm to the outer membrane surface, the
pro-regions are rapidly degraded, leaving only the mature forms that no longer
contain the expected pyroglutamate N-terminal residue. This is an asset for
comparing protein activity independent of issues of protein stability, but it
unfortunately also prevents detection of the pyroglutamylation of the pro-region in
wild-type P. gingivalis strains. Nevertheless, we expect pyroglutamate formation
based on its widespread occurrence (see above), and also because proRgpB is
blocked for Edman degradation in a type IX secretion (T9SS) mutant that retains
non-degraded proRgpB in the periplasm.

We used homologous recombination to construct P. gingivalis W83 strains
expressing RgpAQ24N, RgpBQ25N, RgpBQ25A and KgpQ20N, in ΔRgpB,
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ΔRgpA and wild-type backgrounds, respectively. Due to overlapping RgpA and
RgpB specificities (both enzymes cleave after arginine residues), RgpA activities
had to be compared in ΔRgpB background, and vice versa, whereas Kgp activities
could be compared in a wild-type background. Mutation of the RgpA, RgpB or Kgp
glutamine after the SPI cleavage site did not alter P. gingivalis growth or the
extracellular activity of prolyl tripeptidyl peptidase secreted by P. gingivalis
independent of T9SS. Gingipain activity was assayed in full cultures and the cellfree culture medium from cultures grown to the mid-exponential (OD600 nm = 0.60.8), late exponential/early stationary (OD600 nm = 1.2-1.4) and stationary (OD600 nm
>2.0) phase of growth. We assayed either total extracellular activity, or separately
the activities associated with the outer membrane surface and with the culture
medium. In all cases, activities increased strongly over time from mid-exponential
to late stationary cultures. Mutation of the Q after the SPI cleavage site however,
had surprisingly variable effects on the different gingipains.

The Q24N mutation in RgpA reduced overall activity several-fold, whereas the
equivalent substitution Q25N (and also Q25A) in RgpB and Q20N in Kgp lacked
significant effect, irrespective of whether cells were assayed in mid-exponential,
late exponential/early stationary or late stationary phase (Fig. 10).

For all three gingipains, most of the activity was cell-associated, with only a minor
contribution from protein in the medium. For RgpA, the Q24N decreased cell
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Fig. 10:

Q downstream of the SPI affects RgpA not RgpB or Kgp.

Porphyromonas gingivalis strains were grown in at least six independent cultures
to mid-exponential (OD600 in the range 0.6–0.8), late exponential/early stationary
(OD600 in the range 1.4–1.6) and late stationary phase (OD600 > 2) of growth
then adjusted to the same OD600 of 0.6, 1.4, and 2, respectively. Gingipain activity
was measured in whole cultures with appropriate substrates. One-way ANOVA
tests were carried out separately for the three gingipains (degrees of freedom
RgpA: 5,30; RgpB: 8,45; Kgp: 5,48). Significance was judged applying the
Bonferroni correction for multiple hypotheses (conservatively assuming all against
all comparisons, even though only comparisons between wild-types and mutants
are of interest) for a p = 0.05 threshold. The
¨¨¨¨

¨¨¨

symbol indicates p < 0.001, the

symbol p < 0.0001.

associated activity several fold, in all phases of growth. Activity in the medium was
also significantly reduced in late stationary phase, the only growth stage with more
than a marginal contribution from protein in the medium to the overall activity. In
contrast, for RgpB, both the Q25N (and also Q25A) mutations altered the activity
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associated with cells and in the medium at most insignificantly. There was also no
redistribution of activity between cells and medium. For Kgp, the Q20N substitution
had an unexpected effect. Although the overall activity was not significantly altered,
Q substitution in Kgp increased activity in the medium at the expense of activity
associated with cells, especially in mid-exponential phase, and to a lesser extent
also in late exponential/early stationary phase.

We suspect that the diverse effects of Q substitution must be related to
complicated posttranslational processing of Kgp and RgpA leading to an assembly
of large multidomain complexes of the catalytic and hemagglutinin-adhesion
domains derived from initial polyproteins anchored into the OM via A-LPS [149]
rather than per se translocation of the OM.

QC is Essential for P. gingivalis Survival

Creation of non-polar QC knock-out strains in P. gingivalis was an untenable goal
due to apparent lethality of absence of QC activity. P. gingivalis QC (PG_2157)
lies within an operon containing genes PG_2157, PG_2156, and a HemG
(PG_2158), and in initial attempts downstream effects were present in the gene
replacement (Fig. 11). t. Subsequently we attempted construction of non-polar
knock out strains, without disrupting the operon but it was evident that gene
PG1885 is essential for survival of P. gingivalis bacteria. Partial success was
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achieved with only one survivable mutant in which erythromycin was successfully
inserted between PG_2157 and PG_2158.

PG_2156

PG_2158

PG_2157

Fig. 11: Structural Schematic of the P. gingivalis operon containing QC. Gene
coding sequence PG_2157 (QYT). PgQC lies just prior to PG_2156 and PG_2158
and non-polar disruption of PG_2157 was lethal.

Following these revelations, we shifted focus into examining and manipulating the
possible QC targets that were identified during the SignalP QC distribution data.

P. gingivalis growth attenuation by PgQC Inhibition

After assessing the effects of non-specific inhibitors of QC activity both in vitro and
in vivo, specific inhibitors were produced to experimentally determine the effects
of reduced PgQC activity on bacterial growth. With the assistance and cooperation
of Probiodrug in Germany, banks of specific inhibitors were screened against
purified rPgQC. Promising candidates were then analyzed for inhibition on QC
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activity. The initial inhibitor was LL29. Inhibitor LL29 was dissolved in DMSO into
100mM concentration and incubated with fresh P. gingivalis liquid culture. 1.5ml of
liquid culture of P. gingivalis were lysed, and remaining LL29 inhibitor was washed
with PBS and QC activity was recorded using fluorimetric assay. In these cell
lysates cultures that were administered 100mM LL29 showed a time-dependent
competitive inhibition of PgQC. In addition to the in vitro effects of LL29 on PgQC,
corresponding 1.5 mL cultures of early-log phase P. gingivalis were incubated
overnight to examine the inhibitors’ effect on P. gingivalis growth. After 24-hour
incubation in anaerobic chamber, the OD600 of cultures was analyzed. LL29
inhibitor incubated cultures showed a decrease in absorbance equivalent to 33%
cell density decrease. Initially we suspected that the cell permeability may be a
complicating factor or extracellular inhibitor could be degraded by cell factors. To
effectively rule out inhibitor penetration into bacteria cells, these experiments were
repeated in triplicates but concentrations of LL29 were increased 10 fold to 1mM
and compared to initial 100mM concentration. (Fig. 12)
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P. gingivalis W83 Growth Inhibition
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Fig. 12: LL29 Inhibits P. gingivalis growth. 5 ml of a stock colony of P. gingivalis

equilibrated to OD600 = 0.1 in 3 separate sealed tubes of 5 ml of eTSB media in
triplicate. At inoculation 1mM inhibitor 084 final concentration (DMSO ≤ 1%) was
added or equivalent DMSO ≤ 1% alone was added. Inoculated colonies of P.
gingivalis were subsequently placed in an anaerobic chamber. Statistical difference
(p<0.0001) shown between DMSO and 1mM LL29 are demonstrated with ****.

What is striking is the group with 1mM LL29 showed a remarkable decrease in QC
activity along with a 50% decrease in total liquid culture density (Fig 12). 24-hour
growth curves were plotted to demonstrate LL29’s effect over time (Fig. 12B).
Absorbance reading were taken at 1-hour intervals over a 28-hour period and
plotted to display accurate growth curves. These showed that the cultures with
1mM LL29 only reached an absorbance of less than half of the control group
(DMSO alone). RgpA-null strain cultures were pre-incubated with LL29, pelleted,
washed three times with PBS and then resuspended in fresh eTSB media to
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removed trace amounts of excess LL29 not taken up by the bacteria. This
eliminated excess inhibitor from the reaction. 100mM LL29 demonstrated timedependent inhibiton of W83 in vivo QC activity. This inhibition was more
pronounced at 1mM concentration (Fig. 13).
W83 1mM LL29

W83 100uM LL29

0.3

****
ns

0.4

****

DMSO
100uM LL29

0.2
0.1
0.0

2 hr
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0.3

****
DMSO
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****
****
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Time

Time

Fig. 13: PgQC in vivo inhibition by LL29. Analysis of QC activity in vivo W83 P.
gingivalis. LL29 had a time-dependent inhibitory effect on QC activity at final
concentration 100mM. Whole cell activity was measured after cell lysis. Statistical
difference (p<0.0001) shown between DMSO and 1mM LL29 are demonstrated
with ****.

Samples were then taken at 2, 5, and 8-hour marks and whole cell gingipain activity
assays were completed. Using the data stated above, further screening of potential
specific inhibitor produced 5 additional possible candidates. Inhibitors: 019, 071,
073, 101, and 084 were roughly screened using in vitro PgQC assays. Each
inhibitor showed significant attenuation of PgQC activity but only 084 completely
obliterated QC activity (Fig. 14). Previously, each respective inhibitor was
incubated within the reaction mixture prior to initiation of the assay. In the case of
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084, we wanted to determine if the inhibitor had a bacteriocidal or bacteriostatic
effect, so the growth curve was repeated with addition of 1mM 084 at midlogarithmic bacterial growth (Fig. 14F) After addition of 084, bacterial cell density
decreased slowly up to 24 hrs after which it remained static. This suggests some
mixed bacteriostatic/bacteriocidal killing of P. gingivalis after addition of inhibitor
084 at 1mM final concentration.
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Fig. 14: 24-hour growth Inhibition of P. gingivalis W83. 5 ml of a stock colony
of P. gingivalis equilibrated to OD600 = 0.1 in 3 separate sealed tubes of 5 ml of
eTSB media in triplicate. At inoculation 1mM inhibitor 084 final concentration
(DMSO ≤ 1%) was added or equivalent DMSO ≤ 1% alone was added.
Inoculated colonies of P. gingivalis were subsequently placed in an anaerobic
chamber. Absorbance was measure at each hour for 24 hours. Inhibitor 084 had
the most pronounced effect of inhibition P. gingivalis growth.

68

High Q-values are typical for Bacteroidetes species, but not related phyla

In the following, we call the fraction of signal peptidase I substrates that have a
glutamine immediately downstream of the SPI cleavage site the Q-value. The high
Q-value is not unique for P. gingivalis but is shared with other bacterial species.
LipoP corrected SignalP predictions for various Porphyromonas species suggest
Q-values between 59% (for P. somerae) and 77% (for P. macacae). Manual
inspection of automatic prediction suggested that even the high Q enrichment
values are still underestimated due to the mis-prediction of some signal peptide
cleavage sites.

Porphyromonas species belong to Bacteroidetes, which in turn are placed in the
FCB superphylum containing the Fibrobacteres, Chlorobi, and Bacteroidetes. In
the Bacteroidetes group, 332 of 334 species (i.e. > 99%) had predicted Q-values
above 48%. Averaged across species, the Q-value was 71%, with a standard
deviation for the variation between species of around 10% percent (outliers
included). The two low Q-value outlier species (Bacteroides pectinophilus, 4% and
Candidatus cloacimonas 24%) had a suspiciously low number of predicted
proteins with signal peptides (21 and 83, compared to typically 300 in this group),
suggesting a possible problem with sequencing or annotation rather than a
genuine difference. CELLO predictions for T. forsythia confirm the conclusion for
P. ginigivalis that the enrichment of glutamine residues directly after the SPI
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cleavage site is not specific for proteins of a particular cellular compartment (Table
3). Across the entire FCB superphylum, Q-values were not consistently high. For
most sequenced Chlorobi species, the predicted Q-value was below 9%. Three
outliers were found in this group in little characterized bacteria (annotated as
Chloroherpeton thalassium, Q-value 55%, Chlorobi bacterium, Q-value 63% and
Chlorobium sp., Q-value 67%). Outside the Bacteroidetes and Chlorobi, a
continuum of Q-values was found, ranging from 2% (Chlorobaculum parvum) to
77% (Ignavibacterium album), with no obvious pattern.
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Fig. 15: Q-values averages and Q-value distributions for different groups of
bacteria. The Q-value was determined separately for every species in the groups.
(A) Average Q-values for the species groups (species are given equal weight in
the average), and the standard deviation of Q-values. Bacteroidetes have
significantly higher Q-values than Chlorobi, Spirochoaetes, Chlamydiae, or
cyanobacteria (p < 1E-6 for comparisons of Bacteroidetes against any of the other
species groups according to the Wilcoxon rank sum test). (B) Cumulative Q-value
distributions. For identification of species groups, refer to the symbols in the right
panel (near Q-value 1). The Q-values for Bacteroidetes species are higher than
for the other species groups also judging from cumulative distributions (p < 1E-6
according to the Kolmogorov–Smirnov test). Species were classified as having an
animal- or plant-type QC according to BLASTP searches using the human and A.
thaliana QC.

We also determined the cumulative Q-value distribution for selected bacterial phyla
(Fig. 15), thought to be relatively closely related to Bacteroidetes [150]. Predicted
Q-values for Chlamydiae and Spirochaetes species were typically below 20% and
thus much lower than in Bacteroidetes. Cyanobacterial species typically also had
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lower Q-values. However, in a small fraction of cyanobacterial species (~5%), Qvalues were not much lower than those of Bacteroidetes. High Q-values were for
example found for Scytonema millei (40%), Leptolyngbya valderiana (45%),
Hassallia byssoidea (61%), and Aphanocapsa montana (67%) (Fig 15).

Bacteroidetes have orthologues of animal and plant QCs

We searched complete bacterial proteomes in UNIPROT for orthologues of
animal- and plant-type QCs. In a first step, we used the prototypical human and A.
thaliana QC sequences as queries. In a set of 1878 proteomes, we found 602
animal-type QCs, among them 402 (67%) in Bacteroidetes. We also identified 991
plant-type QCs, among them 401 (40%) in Bacteroidetes. As Bacteroidetes
account for less than 10% of the proteome data (and even less in the redundant
set), it is clear that QCs, particularly of the animal-type, are enriched in the
Bacteroidetes. Orthologues of animal- and plant-type QCs tended to segregate
according to phylogeny. Animal-type QCs were typically found in Bacteroidia,
plant-type QCs in Flavobacteriia. As the number of candidate QCs was smaller
than the number of proteomes, we attempted to enlarge the set of candidate QCs
by carrying out BLASTP queries with representative sequences from Bacteroidia
and Flavobacteriia, the two largest groups within the Bacteroidetes. Starting from
these sequences, and correcting for species duplicates, we identified 574
Bacteroidetes species containing animal-type and 507 Bacteroidetes species
containing plant-type QC enzymes, but only 63 species containing both types of

72

enzymes (E-value threshold 1E-4), compared to 1540 species in the duplication
corrected proteome dataset.

We also attempted iterated searches, using representatives of CD-HIT identified
sequence clusters [151] to initiate additional searches. With this procedure, still
more putative QCs were identified, but the concentration of hits in the
Bacteroidetes phylum was reduced, likely because the set of putative QCs became
contaminated by peptidases. Despite this complication, we can conclude from the
simpler BLASTP searches that most and perhaps even all Bacteroidetes species
have enzymes that could be suitable for glutamine cyclization. In the following, we
focus on the candidate QC enzymes that can be demonstrated in a single BLASTP
step with tight E-value threshold to be orthologous to the prototypical animal- or
plant QC enzymes.

The orthologues of animal and plant-like QCs in Bacteroidetes have intact
active sites

In order to assess the chances that the animal- and plant-type QCs in bacteria
were active, we checked alignments for the presence of key active site residues.
The prototypical animal QC is the human enzyme, hsQC. Its active site is built from
E201 (involved in proton shuttling), D159, E202 (involved in binding the active site
Zn2+ ion), and D248 (involved in both). In the Bacteroidetes orthologues of human
QC, D159, E201 and D248 are highly conserved (>98%). In contrast, E202 is
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conserved only in 9% of Bacteroidetes orthologues, and replaced by an aspartate
residue almost all remaining cases (exceptions <1%). As aspartate and glutamate
can both serve as Zn2+ ligands, we suspect that this substitution may not
compromise activity, or may even be required to accommodate slight changes in
the overall protein structure compared to HsQC. This conclusion is supported by
the observation that an aspartate is also present in the 202 position in the PgQC
enzyme, which we have already shown to be an active QC enzyme.

The prototypical plant QC is the enzyme from C. papaya, CpQC. Its active site is
not as well understood as the active site of hsQC, but it is thought that E69, N155
(probably involved in proton shuttling) and N155, K225 and Q24 (probably involved
in stabilizing the oxyanion intermediate) play a role in catalysis. Among the
Bacteroidetes orthologues, E69, N155 and K225 are strictly conserved. In contrast,
Q24 was conserved only in 81% of cases, and replaced by a glutamate in the
remaining cases. The same substitution occurs in many plant enzymes, and also
in the experimentally studied bacterial Xanthomonas campestris QC (XcQC). In
this special case, the (natural) glutamate variant is still active, albeit an order of
magnitude less so than the engineered glutamine variant [91], suggesting that both
glutamine and glutamate in the active site are compatible with activity, although
not necessarily at the same level.

We conclude from this analysis that Bacteroidetes orthologues of animal and plant
QCs are likely to be active enzymes. This is directly suggestive of QC activity plant
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QC orthologues, and compatible with either QC or aminopeptidase activity for
animal QC orthologues. Classification of the enzymes as lipoproteins (like PgQC)
could strengthen the case for QC activity.

Most Bacteroidetes orthologues of animal and plant QCs are predicted
lipoproteins

Among 401 orthologues of human QC in Bacteroidetes, 323 (~80%) were
predicted lipoproteins, 59 (~15%) were predicted SPI substrates (~15%), and the
remaining 19 (~5%) were predicted to be cytoplasmic. As orthologues of human
QC are highly enriched in Bacteroidetes, relatively few were found in species not
belonging to the Bacteroidetes. Among these, the fraction of predicted lipoproteins
was much smaller. Only 38 (~34%) enzymes were predicted to be lipoproteins, 40
(~36%) were classified as SPI substrates, and remaining 34 (~30%) as cytosolic
proteins.

Among 430 orthologues of A. thaliana QC in Bacteroidetes, 376 were (~87%)
computationally classified as lipoproteins, 20 (~5%) as SPI substrates, and 34
(~8%) as cytoplasmic proteins. The predominance of predicted lipoproteins among
plant-type QCs was much less pronounced when bacterial homologues of plant
QC in general were considered. Among the 1000 bacterial proteins most similar to
A. thaliana QC, predictions classified 475 (~48%) as lipoproteins, 338 (34%) as
SPI substrates, and 175 (18%) as cytosolic proteins.
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Sensitivity (true positive rate, recall) of the LipoP algorithm for gram-negative
bacteria has been reported to be around 90% [140]. The fraction of bacterial QCs
predicted to be lipoproteins in non-Bacteroidetes species is much smaller,
suggesting that not all are lipoproteins. In Bacteroidetes, the fraction of QC
proteins predicted as lipoproteins comes close to the predicted sensitivity of the
prediction algorithm. Thus, it appears likely that most if not all QCs in Bacteroidetes
are lipoproteins, like the prototypical PgQC from P. gingivalis.

Proteomic datasets confirm glutamine cyclization in several Bacteroidetes
species

In order to confirm widespread pyroglutamyl formation in Bacteroidetes, and not
only P. gingivalis, we analyzed additional data from previously reported proteomic
studies [73, 134-137]. In addition to the already discussed 27 proteins from P.
gingivalis, the collated data identify 27 proteins in Tannerella forsythia, 13 in
Parabacteroides distasonis, 8 in Prevotella intermedia and 7 in Cytophaga
hutchinsonii with N-terminal pyroglutamate residue. N-terminal residues other than
pyroglutamate were rare, as predicted from the bioinformatic studies.

Pyroglutamate was not detected at the amino-terminus of all SPI substrates that
are predicted to expose an N-terminal glutamine residue after SPI cleavage, most
likely due to incomplete coverage and not due to selective pyroglutamate
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formation. As already reported for the P. gingivalis proteins, semi-tryptic peptides
were never found to start with glutamine, even though internal tryptic peptides
could be identified with N-terminal glutamine in both modified and unmodified
states. Other circumstantial evidence also supports widespread rather than
selective glutamine cyclization. We focused in particular on the T. forsythia data,
which contained pyroglutamate evidence for the largest number of proteins in one
species. Experimentally detected proteins (by any peptide, not necessarily a
semitryptic peptide) with glutamine after the SPI site were partitioned into proteins
with and without evidence for glutamine cyclization (Figure 16). As already
reported for P. gingivalis, amino acids around the Q were similar in the two groups,
supporting broad QC specificity.

Fig. 16: Sequence downstream of Q in T. forsythia SPI proteins. Comparison
of sequence logos around Q downstream of the signal peptide for T. forsythia SPI
proteins. Top – experimentally demonstrated or

Bottom – undetermined Q

cyclization in OMVs. The signal peptidase motif A-X-A upstream of the SPI
cleavage sites is marked by the arrow. Only proteins with a Q after the predicated
SPI site have been included in the comparison panel in the bottom.
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In addition, QC activity was detectable in T. forsythia using the previous method
for continuous flourimetric QC activity in P. gingivalis (Fig 17).

P. gingivalis vs T. forsythia QC Activity

QC Activity FU/s/µg

0.4

Pg W83
T. forsythia

0.3
0.2
0.1
0.0

W83

T. forsythia

Fig. 17: QC activity in T. forsythia. T. forsythia in the early phase of growth was
measured using whole cell extract, and QC activity was measured in each sample
results given in activity FU/s/µg. QC activity was determined in each fraction
standardized to the volume of washed cells were suspended for sonication. The
QC activity was determined with L-Gln-AMC as a substrate using a coupled assay
with pyroglutamyl aminopeptidase as an auxiliary enzyme. P. gingivalis W83 strain
used here for comparison.

Following this experimentally measured QC activity of a Bacteriodes sp. Other than
P. gingivalis, we decided to test the specificity of LL29 against the T. forsythia QC.
LL29 demonstrated no inhibition of QC activity in vivo at any time point in T.
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forsythia (Fig 18). This could be easily explained by substrate preference or
variability in the active site structural motifs.

No LL29 inhibition in T. forsythia

QC Activity FU/s/µg

0.3

****
DMSO
1mM LL29

0.2

ns
0.1

0.0

W83

T. forsythia

Fig. 18: LL29 Does not inhibit TfQC. T. forsythia in the early phase of growth
was measured using whole cell extract, and QC activity was measured in each
sample results given in activity FU/s/µg. QC activity was determined in each
fraction standardized to the volume of washed cells were suspended for
sonication. The QC activity was determined with L-Gln-AMC as a substrate using
a coupled assay with pyroglutamyl aminopeptidase as an auxiliary enzyme. P.
gingivalis W83 strain used here for comparison. Statistical difference according to
one-way ANOVA (p<0.0001) shown between DMSO and 1mM LL29 are
demonstrated with ****.

Pyroglutamate detection is not consistent for paralogue families in a single
species. Pyroglutamate detection for a protein of a given bacterial species is also
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not predictive for the orthologue in another species. In a first step, we used
BLASTP (E-value threshold 10-9) to identify orthologous proteins in T. forsythia and
P. gingivalis with experimentally verified localization. Only unique pairs were used,
and proteins with more than one paralogue in either species were excluded.
Among the 41 pairs, 9 and 3 were found to have a pyroglutamate at the N-terminal
end. Based on a random association alone, one would then expect experimental
pyroglutamate demonstration for both proteins of a pair in (9*3)/41 ~ 0.7 cases. In
fact, one such case was observed.

Together, the above observations are consistent with general glutamine
cyclization, partially masked by incomplete mass spectrometry coverage (for
example, due to low expression of some proteins, or because semi-tryptic peptides
are too short or too long for efficient mass spectrometry detection). As already
seen for P. gingivalis, pyroglutamate formation was not characteristic for proteins
of a particular compartment, as T. forsythia proteins with pyroglutamate were also
found in the vesicle lumen, in vesicle membranes, and on the vesicle surface of
OMVs, which represent periplasmic, integral OM and cell-surface associated
proteins, respectively.
A model for pyroglutamate formation in proteins destined to the periplasm,
the outer membrane, the outer membrane surface, or the medium

Together, this body of data suggest a model for Bacteridetes SPI substrates that
reside in or transit through the periplasm. Their signal peptides are cleaved by SPI,
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a lipoprotein with active site on the periplasmic face of the inner membrane.
Because of the enrichment of glutamine immediately downstream of the SPI
cleavage site, this reaction typically exposes an amino-terminal glutamine residue.
QC, another lipoprotein, also with active site on the periplasmic face of the inner
membrane, is then ideally positioned to catalyze the cyclization of the glutamine
residue to a pyroglutamate residue. The cooperation between SPI and QC is
apparently efficient, suggesting either direct interaction or joint anchoring in lipid
domains, which we have not yet tested. Pyroglutamate formation occurs for
proteins that remain in the periplasm, as well as for proteins that are transported
further into or through the outer membrane. We suggest the term “Q-rule” to
describe the finding that glutamines are enriched after SPI cleavage sites, and that
these glutamine residues are cyclized to form N-terminal pyroglutamate residues
in proteins that are destined to the periplasm or beyond (Fig. 19).
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Fig. 19: Hypothesized Pathway for Pyroglutamate formation by QC.
Schematic representation of the pathway for pyroglutamate formation at the amino
terminus of proteins that transit to or through the periplasm. It is currently unclear
whether or not SPI and QC are physically associated. Pyroglumate formation has
not yet been tested for proteins of the inner membrane.

Importance of the Q-rule pathway

The Q-rule pathway seems to be biologically important, not only judging by the
number of proteins that are subject to the rule. P. gingivalis glutaminyl cyclase is
present in both virulent and avirulent strains [152]. According to an unbiased large
scale transposon mutagenesis screen [153], the enzyme is essential even in
laboratory culture conditions when P. gingivalis is not pitted against a host immune
system. It is currently unclear why the enzyme is essential. Our data speak against
a role of the modification in protein sorting. Given the host-associated lifestyle of
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many Bacteroidetes species, it is possible that glutaminyl cyclization protects
secreted proteins against host aminopeptidases (excluding of course the host
pyroglutamate aminopeptidases). However, this model does not explain why the
Q-rule applies to SPI substrates that remain in the periplasm or why the glutaminyl
cyclase is essential for P. gingivalis in culture conditions, unless P. gingivalis has
become unable to do without the Q-rule and now needs pyroglutamate formation
for protection against its own periplasmic proteases as well. Further lending
credence to this theory is the lethality of QC knock-outs.

Future topics

One of the lingering questions remaining is how the QC and SPI interact withing
the periplasmic space. It was not evaluated whether these are or are not in intimate
contact or physically linked to one another, although their function is clearly linked.
Another point of interest is perhaps although only downstream effects of gingipain
secretion were evaluated in this project, P. gingivalis is fully capable of surviving
without gingipain activity. Perhaps another essential protein or proteins processed
through this system is blocked, thereby leading to cell death. Either way this
system poses as a possible target for future studies and continued research.
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